Leerink Swann reiterated their market perform rating on shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) in a research report sent to investors on Tuesday, January 2nd, MarketBeat Ratings reports. They currently have a $15.00 target price on the biopharmaceutical company’s stock. Leerink Swann also issued estimates for Sucampo Pharmaceuticals’ FY2019 earnings at $1.79 EPS, FY2020 earnings at $2.02 EPS and FY2021 earnings at $2.19 EPS.
Several other research firms also recently issued reports on SCMP. B. Riley downgraded Sucampo Pharmaceuticals from a buy rating to a neutral rating and set a $18.00 price target for the company. in a research note on Tuesday, December 26th. ValuEngine raised Sucampo Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Sunday, December 31st. Maxim Group cut Sucampo Pharmaceuticals to a hold rating in a research report on Monday, January 1st. Nomura started coverage on Sucampo Pharmaceuticals in a research report on Monday, December 18th. They set a buy rating and a $43.00 price objective for the company. Finally, Instinet started coverage on Sucampo Pharmaceuticals in a research report on Tuesday, December 19th. They set a buy rating and a $43.00 price objective for the company. Six research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Sucampo Pharmaceuticals presently has a consensus rating of Buy and a consensus target price of $21.58.
Shares of Sucampo Pharmaceuticals (SCMP) opened at $17.95 on Tuesday. The stock has a market capitalization of $837.13, a PE ratio of -5.36, a PEG ratio of 5.04 and a beta of 1.45. Sucampo Pharmaceuticals has a 52 week low of $9.30 and a 52 week high of $18.75. The company has a debt-to-equity ratio of 7.37, a quick ratio of 4.46 and a current ratio of 5.11.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.02. The company had revenue of $61.27 million during the quarter, compared to the consensus estimate of $58.05 million. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The firm’s revenue was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.30 EPS. research analysts expect that Sucampo Pharmaceuticals will post 1.12 earnings per share for the current year.
In other news, insider Peter A. Kiener sold 50,000 shares of the stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $16.50, for a total value of $825,000.00. Following the completion of the transaction, the insider now directly owns 52,023 shares of the company’s stock, valued at approximately $858,379.50. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 4.13% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of SCMP. Schwab Charles Investment Management Inc. raised its holdings in shares of Sucampo Pharmaceuticals by 36.9% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 246,796 shares of the biopharmaceutical company’s stock worth $2,592,000 after buying an additional 66,493 shares in the last quarter. Arizona State Retirement System grew its position in Sucampo Pharmaceuticals by 1.6% during the 2nd quarter. Arizona State Retirement System now owns 13,100 shares of the biopharmaceutical company’s stock worth $138,000 after acquiring an additional 200 shares during the last quarter. Rhumbline Advisers grew its position in Sucampo Pharmaceuticals by 0.9% during the 2nd quarter. Rhumbline Advisers now owns 48,810 shares of the biopharmaceutical company’s stock worth $513,000 after acquiring an additional 423 shares during the last quarter. State of Wisconsin Investment Board bought a new stake in Sucampo Pharmaceuticals during the 2nd quarter worth approximately $199,000. Finally, SG Americas Securities LLC grew its position in Sucampo Pharmaceuticals by 5.6% during the 2nd quarter. SG Americas Securities LLC now owns 11,977 shares of the biopharmaceutical company’s stock worth $126,000 after acquiring an additional 631 shares during the last quarter. 64.55% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This piece of content was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/21/sucampo-pharmaceuticals-scmp-stock-rating-reaffirmed-by-leerink-swann.html.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.